Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Transplantation and investigational therapies
7 evidence topics · 8 sources
Investigational agents and modalities named in the 2025 guideline
“Other experimental therapies include the orally administered agents efavirenz, a non‐nucleoside reverse transcriptase antiretroviral inhibitor, and nizubaglustat, a selective dual inhibitor of ceramide glucosyltransferase and non‐lysosomal neutral glucosylceramidase (NLGase)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, several other therapeutic modalities, including gene therapy, antisense oligonucleotide (ASO) therapy for patients with specific targetable mutations, and CRISPR/Cas9 technology in animal studies, are underway with positive preliminary findings” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Gene and cell-based therapies remain preclinical
“Gene therapy and cell‐based therapies (mesenchymal stem cells) have gained much interest in the pre‐clinical setting,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but there have been no clinical trials to our knowledge to date.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Nizubaglustat phase 3 trial in late-infantile and juvenile forms
Efavirenz phase 2 trial in adult and late juvenile-onset disease
“This is a single-center, phase II clinical trial to evaluate the efficacy and safety of Efavirenz in addition to standard of care in patients diagnosed with adult or late juvenile-onset NPC with cognitive impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All enrolled patients will be treated orally with 25 mg/d of Efavirenz for 52 weeks (1 year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review assessment of evidence for investigational agents
Allogeneic bone marrow transplantation in NPC2: case reports
“In this report we describe the first successful allogeneic bone marrow transplantation for this condition in a 16-month-old boy homozygous for the NPC2 p.E20X mutation, which has hitherto been reported to cause disease with a severe phenotype.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This 'graft versus substrate' reaction was managed with intensive immune suppressant therapy, and it gradually resolved as the substrate was cleared by the engrafted donor macrophages.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to the previously reported patients with the same mutations, our patient has no respiratory compromise and has made some developmental progress (especially gross motor), though is significantly delayed (particularly in speech and language).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Haematopoietic stem cell transplantation (HSCT) could be considered for patients with this mutation as long as performed early in the course of the disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Liver transplantation in children with neonatal liver failure: case series
“Nine children were identified (six centres).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neonatal acute liver failure was the most common indication for LTx (seven children).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological symptoms developed in 4/7 (57%) patients at median 9 (range: 5–13) years following LTx.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Neurological disease is not prevented in the majority of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“LTx still remains controversial in NPC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote